229,785 Shares in Arcellx, Inc. (NASDAQ:ACLX) Bought by Artia Global Partners LP

Artia Global Partners LP bought a new stake in Arcellx, Inc. (NASDAQ:ACLX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 229,785 shares of the company's stock, valued at approximately $17,622,000. Arcellx makes up 6.3% of Artia Global Partners LP's holdings, making the stock its 4th largest position. Artia Global Partners LP owned 0.42% of Arcellx at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. Gilead Sciences Inc. purchased a new position in shares of Arcellx during the fourth quarter worth approximately $515,418,000. FMR LLC increased its position in Arcellx by 22.8% in the 4th quarter. FMR LLC now owns 7,956,633 shares of the company's stock valued at $610,194,000 after acquiring an additional 1,477,360 shares during the period. Vanguard Group Inc. raised its stake in Arcellx by 35.3% during the 4th quarter. Vanguard Group Inc. now owns 3,330,092 shares of the company's stock valued at $255,385,000 after acquiring an additional 867,996 shares during the last quarter. Capital World Investors acquired a new position in shares of Arcellx in the fourth quarter valued at approximately $19,393,000. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Arcellx by 11.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,121,322 shares of the company's stock worth $162,685,000 after purchasing an additional 220,711 shares during the last quarter. Hedge funds and other institutional investors own 96.03% of the company's stock.

Arcellx Trading Up 1.9 %

Shares of ACLX traded up $1.24 during mid-day trading on Friday, hitting $66.77. The company's stock had a trading volume of 161,276 shares, compared to its average volume of 552,095. Arcellx, Inc. has a 1-year low of $47.88 and a 1-year high of $107.37. The firm has a market capitalization of $3.68 billion, a P/E ratio of -93.75 and a beta of 0.33. The firm has a 50-day simple moving average of $64.84 and a 200 day simple moving average of $74.22.

Arcellx (NASDAQ:ACLX - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.24). The company had revenue of $15.27 million for the quarter, compared to analyst estimates of $27.42 million. Arcellx had a negative net margin of 25.94% and a negative return on equity of 8.28%. As a group, sell-side analysts predict that Arcellx, Inc. will post -1.58 EPS for the current fiscal year.

Insider Buying and Selling at Arcellx

In related news, Director Kavita Patel sold 1,500 shares of Arcellx stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $63.16, for a total value of $94,740.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Christopher Heery sold 10,155 shares of the company's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $63.79, for a total value of $647,787.45. Following the sale, the insider now owns 37,486 shares of the company's stock, valued at $2,391,231.94. This represents a 21.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 55,955 shares of company stock valued at $3,504,758 over the last quarter. Corporate insiders own 6.24% of the company's stock.

About Arcellx

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).